Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

Blood (2010) 116 (21): 3375.

https://doi.org/10.1182/blood.V116.21.3375.3375

Published: 2010

Journal Articles

Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical and Histopathological Implications.

Luigi Gugliotta, MD, Stefano Ascani, MD, Silvia Asioli, MD, Emanuela Boveri, MD, G. Fraternali Orcioni, MD, Umberto Gianelli, MD, Elena Sabattini, MD, Francesco Passamonti, MD, Franca Radaelli, MD, Alessia Tieghi, MD, Claudio Tripodo, MD, Riccardo Valli, MD, Nicola Vianelli, MD, Vito Franco, MD

Blood (2009) 114 (22): 4974.

https://doi.org/10.1182/blood.V114.22.4974.4974

Published: 2009

Journal Articles

An Unusual Case of ‘Delayed‘ Febrile Non Hemolytic Transfusion Reaction in a Thalassemia Major Patient with Asymptomatic Plasmodium Falciparum Infection.

Carla Boschetti, Franca Radaelli, Mariangela Colombi, Cristina Vercellati, Luisa Caspani, Romualdo Grande, Maria Domenica Cappellini, Alberto Zanella

Blood (2009) 114 (22): 4186.

https://doi.org/10.1182/blood.V114.22.4186.4186

Published: 2009

Journal Articles

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Francesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, Marilina Amabile, Gabriele Gugliotta, Angela Poerio, Massimo Breccia, Enrico Gottardi, Bruno Martino, Ivana Pierri, Fabrizio Quarantelli, Franca Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani

Blood (2009) 114 (22): 2192.

https://doi.org/10.1182/blood.V114.22.2192.2192

Published: 2009

Journal Articles

Chronic Myeloid Leukemia (CML) Patients with “Suboptimal” Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to “Optimal” Responders: A GIMEMA CML WORKING PARTY Analysis.

Blood (2009) 114 (22): 2196.

https://doi.org/10.1182/blood.V114.22.2196.2196

Published: 2009

Journal Articles

Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.

Blood (2009) 114 (22): 2164.

https://doi.org/10.1182/blood.V114.22.2164.2164

Published: 2009

Journal Articles

Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data

Blood (2008) 112 (11): 5248.

https://doi.org/10.1182/blood.V112.11.5248.5248

Published: 2008

Journal Articles

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Blood (2008) 112 (11): 2118.

https://doi.org/10.1182/blood.V112.11.2118.2118

Published: 2008

Journal Articles

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

Claudia Vener, Nicola Stefano Fracchiolla, Umberto Gianelli, Rossella Calori, Franca Radaelli, Alessandra Iurlo, Sabrina Caberlon, Giancarla Gerli, Leonardo Boiocchi, Giorgio Lambertenghi Deliliers

Blood (2008) 111 (4): 1862–1865.

https://doi.org/10.1182/blood-2007-09-112953

Published: 2008

Journal Articles

Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).

Lorella Melillo, MD, Daniela Valente, MD, Alessia Tieghi, MD, Anna Candoni, MD, Bruno Martino, MD, Rosanna Ciancia, MD, Vincenzo Martinelli, MD, Franca Radaelli, MD, Giorgina Specchia, MD, Roberto Latagliata, MD, Potito R. Scalzulli, MD, Fausto Palmieri, MD, Michele Cedrone, MD, Nicola Cascavilla, MD, Luigi Gugliotta

Blood (2007) 110 (11): 2549.

https://doi.org/10.1182/blood.V110.11.2549.2549

Published: 2007

Journal Articles

Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Expression Is Increased in Ph − Chronic Myeloproliferative Disorders and Correlates with the Microvessel Density and VEGF.

Giorgio Lambertenghi Deliliers, MD, Umberto Gianelli, MD, Claudia Vener, MD, Nicola S. Fracchiolla, MD, Elisa De Camilli, MD, Leonardo Boiocchi, MD, Rossella Calori, MD, Alessandra Iurlo, MD, Franca Radaelli, MD, Silvano Bosari, MD, Guido Coggi, MD

Blood (2007) 110 (11): 1554.

https://doi.org/10.1182/blood.V110.11.1554.1554

Published: 2007

Journal Articles

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Simona Soverini, Alessandra Gnani, Sabrina Colarossi, Fausto Castagnetti, Elisabetta Abruzzese, Serena Merante, Massimo Breccia, Adele Capucci, Giorgina Specchia, Franca Radaelli, Francesca Palandri, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2007) 110 (11): 1934.

https://doi.org/10.1182/blood.V110.11.1934.1934

Published: 2007

Journal Articles

Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.

Clara Ricci, MS, Francesco Onida, MD, Katia Todoerti, MS, Franca Radaelli, MD, Antonino Neri, MD, Riccardo Ghidoni, PhD, Giorgio Lambertenghi Deliliers, MD

Blood (2007) 110 (11): 4196.

https://doi.org/10.1182/blood.V110.11.4196.4196

Published: 2007

Journal Articles

The Registro Italiano Trombocitemie (GIMEMA Project): Preliminary Analysis of the First 801 Enrolled Patients.

Blood (2006) 108 (11): 3639.

https://doi.org/10.1182/blood.V108.11.3639.3639

Published: 2006

Journal Articles

Immunohistochemical Expression of Vascular Endothelial Growth Factor Correlates with Microvessel Density in Ph − Chronic Myeloproliferative Disorders.

Claudia Vener, MD, Umberto Gianelli, MD, Paola Rafaniello Raviele, MD, Federica Savi, MD, Francesco Somalvico, BS, Rossella Calori, MD, Paolo Bucciarelli, MD, Alessandra Iurlo, MD, Franca Radaelli, MD, Silvano Bosari, MD, Giorgio Lambertenghi Deliliers, MD

Blood (2006) 108 (11): 2698.

https://doi.org/10.1182/blood.V108.11.2698.2698

Published: 2006

Journal Articles

Imatinib 400 mg in Early Chronic Phase CML: Results of a Multicentric, Prospective Non Academical Observational Study (by the GIMEMA CML Working Party).

Blood (2006) 108 (11): 4777.

https://doi.org/10.1182/blood.V108.11.4777.4777

Published: 2006

Journal Articles

Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.

Elisabetta Abruzzese, MD, Alessandro Gozzetti, MD, Nicoletta Testoni, PhD, Alfonso Zaccaria, MD, Franca Radaelli, MD, Sara Galimberti, MD, Malgorzata M. Trawinska, MD, Marco Mancini, MD, Dario Ferrero, MD, Michela Salvio, MD, Federica Sora’, MD, Monica Crugnola, MD, Michele Cedrone, MD, Gianantonio Rosti, MD, Sergio Amadori, MD, Paolo de Fabritiis, MD, Michele Baccarani, MD

Blood (2006) 108 (11): 2116.

https://doi.org/10.1182/blood.V108.11.2116.2116

Published: 2006

Journal Articles

Essential Thrombocythemia: Analysis of Risk Factors for Thrombotic Events in a Series of 306 Patients.

Franca Radaelli, MD, Stefania Bramanti, MD, Mariangela Colombi, MD, Alessandra Iurlo, MD, Alberto Zanella, MD

Blood (2005) 106 (11): 4937.

https://doi.org/10.1182/blood.V106.11.4937.4937

Published: 2005

Journal Articles

Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.

Simona Soverini, Sabrina Colarossi, Alessandra Gnani, Gianantonio Rosti, Fausto Castagnetti, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Panagiota Giannoulia, Elisabetta Abruzzese, Ester Orlandi, Franca Radaelli, Fabrizio Ciccone, Mario Tiribelli, Clementina Caracciolo, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli

Blood (2005) 106 (11): 435.

https://doi.org/10.1182/blood.V106.11.435.435

Published: 2005

Journal Articles

Ph-Abnormal Clones Emerged during Imatinib Therapy: Clinical Report and Clonal Analyses on 23 Patients from GIMEMA Working Party (GWP) in CML Registry.

Elisabetta Abruzzese, MD, Alessandro Gozzetti, MD, Alfonso Zaccaria, MD, Nicoletta Testoni, MD, Sara Galimberti, MD, Malgorzata M. Trawinska, MD, Tommaso Caravita, MD, Paola Panetta, BS, Marco Mancini, MD, Dario Ferrero, MD, Michela Salvio, MD, Franca Radaelli, MD, Federica Sora’, MD, Gianantonio Rosti, Sergio Amadori, MD, Michele Baccarani, MD

Blood (2004) 104 (11): 2936.

https://doi.org/10.1182/blood.V104.11.2936.2936

Published: 2004

NARROW

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

Bone Marrow Biopsy Revision According to WHO Criteria in 272 Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Report On Clinical and Histopathological Implications.

An Unusual Case of ‘Delayed‘ Febrile Non Hemolytic Transfusion Reaction in a Thalassemia Major Patient with Asymptomatic Plasmodium Falciparum Infection.

The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.

Chronic Myeloid Leukemia (CML) Patients with “Suboptimal” Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to “Optimal” Responders: A GIMEMA CML WORKING PARTY Analysis.

Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.

Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis

Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).

Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Expression Is Increased in Ph − Chronic Myeloproliferative Disorders and Correlates with the Microvessel Density and VEGF.

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.

The Registro Italiano Trombocitemie (GIMEMA Project): Preliminary Analysis of the First 801 Enrolled Patients.

Immunohistochemical Expression of Vascular Endothelial Growth Factor Correlates with Microvessel Density in Ph − Chronic Myeloproliferative Disorders.

Imatinib 400 mg in Early Chronic Phase CML: Results of a Multicentric, Prospective Non Academical Observational Study (by the GIMEMA CML Working Party).

Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.

Essential Thrombocythemia: Analysis of Risk Factors for Thrombotic Events in a Series of 306 Patients.

Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.

Ph-Abnormal Clones Emerged during Imatinib Therapy: Clinical Report and Clonal Analyses on 23 Patients from GIMEMA Working Party (GWP) in CML Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only